These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10189399)

  • 1. Phenotypic changes in neutrophils after rhG-CSF administration in non-Hodgkin's lymphoma patients undergoing PBSC transplantation or conventional chemotherapy.
    Carulli G; Papineschi F; Benedetti E; Vanacore R; Azzarà A; Petrini M
    Haematologica; 1999 Mar; 84(3):281-3. PubMed ID: 10189399
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
    Azzarà A; Carulli G; Rizzuti-Gullaci A; Capochiani E; Petrini M
    Am J Hematol; 2001 Apr; 66(4):306-7. PubMed ID: 11279646
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
    Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
    Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
    Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
    Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [G-CSF administration following autologous peripheral blood stem cell transplantation--the effect of G-CSF level on neutrophil recovery].
    Saigo K; Sugimoto T; Matsuo M; Narita H; Ryo R; Kumagai S
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):437-42. PubMed ID: 10740638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M; Al-Kgodary T
    Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
    Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
    Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of blood cells during peripheral blood stem cell mobilization following chemotherapy in patients with non-Hodgkin's lymphoma].
    Okada Y; Ando M; Kato T; Taji H; Kagami Y; Ogura M; Morishima Y
    Rinsho Ketsueki; 2000 Feb; 41(2):91-6. PubMed ID: 10723236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
    Copelan E; Pohlman B; Rybicki L; Kalaycio M; Sobecks R; Andresen S; Dean R; Koo A; Chan J; Sweetenham J; Bolwell B
    Bone Marrow Transplant; 2009 Jan; 43(2):101-5. PubMed ID: 18794865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
    Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor differently modifies actin polymerization in neutrophils.
    Zucca A; Brizzi S; Riccioni R; Azzarà A; Ghimenti M; Carulli G
    Clin Ter; 2006; 157(1):19-24. PubMed ID: 16669548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.
    Vantelon JM; Koscielny S; Brault P; Bourhis JH; Ribrag V; Pico J; Fenaux P; Munck JN
    Bone Marrow Transplant; 2000 Mar; 25(5):495-9. PubMed ID: 10713625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
    Chou T; Ishiguro T; Imajo K; Kawano F; Gondo H; Kasai M; Masuda M; Koike M; Shimazaki C; Hara M; Shinagawa K; Ogawa M; Takaku F; Harada M
    Rinsho Ketsueki; 1999 Oct; 40(10):1058-67. PubMed ID: 10565222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motility of rhG-CSF-induced neutrophils in patients undergoing chemotherapy: evidence for inhibition detected by image analysis.
    Azzarà A; Carulli G; Rizzuti-Gullaci A; Minnucci S; Capochiani E; Ambrogi F
    Br J Haematol; 1996 Jan; 92(1):161-8. PubMed ID: 8562391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.